Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentler brain stimulation replace ECT for tough depression?

NCT ID NCT06682299

Disease control Sponsor: Austin Messner Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether people with treatment-resistant depression who got better with electroconvulsive therapy (ECT) could switch to a less intense treatment called transcranial magnetic stimulation (TMS) to stay well. TMS is done in a clinic without anesthesia and has fewer memory side effects. Only one person took part before the study ended early, so we don't have clear results yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Apr 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients treated for TRD who have achieved remission through an index series of ECT * Able to provide informed consent * Age between 18 and 65 years * Deemed appropriate for maintenance TMS by their psychiatrist * Right-handed Exclusion Criteria: * History of seizures or a seizure disorder * Related neurological disorder, or any other medical condition that would preclude TMS treatment determined by the treatment team.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Treatment resistant depression (TRD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Depressive Disorder, Treatment-Resistant Epilepsy, Rolandic major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Treatment resistant depression (TRD)

Contacts and locations

Locations

  • University of Kentucky

    Lexington, Kentucky, 40509, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.